THE PATIENT PERSPECTIVE IN HEALTH TECHNOLOGY ASSESSMENT REIMBURSEMENT DECISIONS FOR ORPHAN DRUGS ACROSS DIFFERENT COUNTRIES

Author(s)

Nicholson L1, Langham S2, Adkins E1
1Maverex limited, Manchester, UK, 2Maverex limited,, Manchester, UK

OBJECTIVES

There is growing recognition that the patient perspective is fundamental in assessing the value of new treatments in health technology assessment (HTA). This is particularly relevant for orphan drugs (ODs) as there is often limited evidence describing disease burden and unmet need, and the impact of treatment on patients’ day-to-day lives may not be fully captured in clinical trials. This study reviewed how patient input was provided and how it influenced reimbursement decisions in recent HTAs of ODs from countries that commonly include patient input as part of their HTA process.

METHODS

We searched HTA agency websites (www.pbs.gov.au [Australia], www.cadth.ca, www.cadth.ca/pcodr [Canada], www.nice.org.uk [England], and www.scottishmedicines.org.uk [Scotland]) to identify HTAs of the 46 ODs that received European marketing authorisation from 2016 to 2018.

RESULTS

We identified 47 HTAs relating to 22 ODs: 8 in Australia, 8 in Canada, 15 in England, and 16 in Scotland; input from patients/patient advocacy groups was included in 50%, 100%, 87%, and 94% of HTAs, respectively. A high proportion of HTAs included patient input (85%), with 92% of those being positive reimbursement recommendations. However, the type of input presented differed between HTA agencies, from a focus only on unmet need in England to an input on unmet need, clinical efficacy, tolerability, quality of life improvements, and treatment convenience in Scotland. Positive HTA decisions were reported in 33% (1/3) HTAs in Australia that included patient input, 92% (12/13) in Scotland and 100% in Canada and England.

CONCLUSIONS :

Patient input into HTA decision making varied between countries. Despite a generally positive association between patient input and decision, the impact of patient involvement on final HTA decisions remains unclear. There is a need for HTA agencies to formalise patient participation and publish criteria demonstrating how it is incorporated into the decision-making process, particularly for orphan diseases.

Conference/Value in Health Info

2019-11, ISPOR Europe 2019, Copenhagen, Denmark

Code

PRO103

Topic

Health Technology Assessment

Topic Subcategory

Decision & Deliberative Processes

Disease

Rare and Orphan Diseases

Your browser is out-of-date

ISPOR recommends that you update your browser for more security, speed and the best experience on ispor.org. Update my browser now

×